Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotypeFollowing recent approvals in the EU and China, the US approval is ...
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...
The global pulmonary function testing devices market revenue was around US$ 2.0 billion in 2022 and is estimated to reach US$ 3.5 billion by 2031, growing at a compound annual growth rate (CAGR) of ...